CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH In an editorial accompanying the final results of the TOURMALINE-MM1 study, Drs. D’Souza and Lonial question whether overall survival (OS) is “still the gold standard for demonstrating the value of a novel agent in phase III trials early in the disease course given the current treatment landscape.”
Peer-influenced content. Sources you trust. No registration required. This is HCN.
